CareDx (CDNA) Expected to Announce Quarterly Earnings on Wednesday

CareDx (NASDAQ:CDNA - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, April 30th. Analysts expect CareDx to post earnings of $0.06 per share and revenue of $84.56 million for the quarter.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $1.46. The company had revenue of $86.58 million during the quarter, compared to analysts' expectations of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Price Performance

CareDx stock traded down $0.70 during mid-day trading on Monday, reaching $17.79. The stock had a trading volume of 142,416 shares, compared to its average volume of 794,225. CareDx has a one year low of $7.61 and a one year high of $34.84. The company has a market capitalization of $985.75 million, a price-to-earnings ratio of -6.57 and a beta of 2.18. The company has a 50-day moving average price of $19.07 and a two-hundred day moving average price of $21.81.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and reduced their price target for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. Stephens reissued an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Thursday, February 27th. StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a research note on Wednesday, February 26th. HC Wainwright dropped their target price on CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Finally, The Goldman Sachs Group dropped their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.